Bioline Rx (BLRX) AI Stock Analysis

Bioline Rx

(TASE:BLRX)

Select Model

Rating:45Neutral

Price Target:ILA 1.00▲(0.00% Upside)

Action:reiterated

Date:10/27/26

The overall score of 45 reflects a high-risk, early-stage biotech company. The most significant factor is the weak financial performance, characterized by deep unprofitability and cash burn, which is partially offset by a promising earnings call highlighting strong clinical progress for its lead asset, GLIX1. Bearish technicals and a negative P/E ratio further weigh on the score, underscoring the stock's speculative nature.

Positive Factors

Differentiated GLIX1 platformGLIX1 combines a differentiated mechanism with blood-brain barrier penetration and activity in glioblastoma models, addressing a severe unmet need. If clinical findings validate the preclinical profile, these attributes could support meaningful differentiation and broader partnering interest.

Negative Factors

Collapsed revenue and deep lossesThe sharp revenue decline and very negative net margin show that current commercial income is insufficient to support the company's operating base. This weak earnings profile increases dependence on milestones, royalties, partnerships, or external capital to sustain development.

Bioline Rx (BLRX) vs. iShares MSCI Israel ETF (EIS)

Market Cap: ILS 29.87M
Dividend Yield: ―
Average Volume (3M): 3.55M
Price to Earnings (P/E): -1.0
Beta (1Y): 0.44
Revenue Growth: -93.07%
EPS Growth: 62.25%
Country: Israel
Employees: 22
Sector: General
Sector Strength: 55
Industry: Biotechnology

Bioline Rx Business Overview & Revenue Model

Company Description

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatm...

How the Company Makes Money

BiolineRx generates revenue primarily through (1) collaboration/licensing arrangements and (2) to a lesser extent, other operating income typical of development-stage biotech companies. Under collaboration or licensing deals, the company may receive...

Bioline Rx Earnings Call Summary

Earnings Call Date:Aug 30, 2026(Q2-2026)|% Change Since:-33.33%|Next Earnings Date:May 26, 2025

Earnings Call SentimentPositive

The call was predominantly positive, driven by strong GLIX1 clinical recruitment and tolerability, encouraging preclinical efficacy and combination data, progress in the pancreatic cancer trial, APHEXDA royalty generation, and funding expected to support operations into the first half of 2027. These positives were tempered by the higher quarterly net loss and R&D spending, flat revenue, the early stage of GLIX1 clinical development, uncertainty surrounding the pancreatic cancer treatment landscape, and the commercial work still required to expand APHEXDA adoption.

Positive Updates

GLIX1 Clinical Trial Progressing Ahead of Plan

BioLineRx reported that recruitment to the Phase I/IIa GLIX1 trial in glioblastoma and other high-grade gliomas is going extremely well and that the trial continues to progress according to plan. Dosing began in the second of five planned Phase I cohorts last month, with the third cohort expected to begin dosing in September. The company has been pleased with GLIX1's safety and tolerability more than four months into the study and continues to anticipate Phase I data in the first half of 2027.

Negative Updates

Net Loss Increased Year Over Year

Net loss for the quarter ended June 30, 2026, was $4.3 million compared with $3.9 million in the 2025 quarter, an increase of $0.4 million, or approximately 10%.

Company Guidance

BioLineRx expects the third of 5 planned GLIX1 Phase I cohorts to commence dosing in September, with the Phase I part expected to recruit up to 30 patients and Phase I data anticipated in the first half of 2027; the Phase IIa expansion is planned to include additional cohorts, including GBM, newly diagnosed and/or recurrent, as well as additional cancers with or without standard of care, for example, PARP inhibitors. The CheMo4METPANC trial’s prespecified interim/futility analysis is planned for when 40% of progression-free survival events are observed, expected later this year. Cash and equivalents of $13.1 million are sufficient to fund the operating plan as currently contemplated into the first half of 2027, and the $3.75 million offering is expected to close later today.

Bioline Rx Financial Statement Overview

Summary

Financial performance is weak. While new TTM revenue and a 69.9% gross margin are positive, the company is deeply unprofitable with a -571.6% net margin and is burning cash, with -$10.9M in operating cash flow. The balance sheet shows reduced leverage, but ongoing losses continue to erode equity.

Income Statement

35Negative

Balance Sheet

55Neutral

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Mar 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.40M	1.28M	28.94M	4.80M	0	0
Gross Profit	976.95K	462.21K	19.68M	1.11M	0	0
EBITDA	-11.31M	-10.61M	3.92M	-57.09M	-28.50M	-24.07M
Net Income	-8.04M	-1.27M	-9.22M	-60.61M	-20.75M	-28.14M
Balance Sheet
Total Assets	33.26M	40.91M	38.91M	63.92M	76.38M	81.39M
Cash, Cash Equivalents and Short-Term Investments	12.99M	20.88M	19.56M	42.99M	51.08M	57.13M
Total Debt	7.94M	10.15M	15.04M	11.59M	12.32M	4.65M
Total Liabilities	16.75M	17.56M	25.45M	50.70M	25.54M	13.30M
Stockholders Equity	13.68M	18.20M	13.46M	13.22M	50.84M	68.09M
Cash Flow
Free Cash Flow	-10.97M	-8.77M	-43.93M	-22.91M	-26.56M	-23.67M
Operating Cash Flow	-10.94M	-8.74M	-43.87M	-22.61M	-26.24M	-23.57M
Investing Cash Flow	12.53M	-9.25M	29.37M	1.44M	4.01M	-38.22M
Financing Cash Flow	-4.78M	9.62M	20.66M	15.06M	20.44M	57.75M

Bioline Rx Technical Analysis

Technical Analysis SentimentNegative

Last Price1.00

Price Trends

50DMA1.30Negative

100DMA1.41Negative

200DMA1.43Negative

Market Momentum

MACD-0.07Positive

RSI35.69Neutral

STOCH33.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BLRX, the sentiment is Negative. The current price of 1.00 is below the 20-day moving average (MA) of 1.15, below the 50-day MA of 1.30, and below the 200-day MA of 1.43, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 35.69 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BLRX.

Bioline Rx Risk Analysis

Bioline Rx disclosed 43 risk factors in its most recent earnings report. Bioline Rx reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine.Q4, 2021

Bioline Rx Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IL:BLRX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IL:PPBT	46Neutral	ILS 32.42M	-0.01	―	―	―	-125.74%
IL:BLRX	45Neutral	ILS 29.87M	-1.03	―	―	-93.07%	62.25%
IL:BOLT	37Underperform	ILS 26.88M	-2.21	―	―	-100.00%	-29.02%
IL:CANF	37Underperform	ILS 15.98M	-0.24	―	―	―	―

* General Sector Average

Performance Comparison

IL:BLRX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IL:BLRX	BioLineRX Ltd.	1.00	-1.00	-50.00%
IL:XTLB	XTL Biopharmaceuticals Ltd.	1.40	-2.50	-64.10%
IL:CANF	Can-Fite BioPharma Ltd.	263.30	262.30	26230.00%
IL:BOLT	BioLight Life Sciences Ltd.	296.10	-109.00	-26.91%
IL:PPBT	Purple Biotech Ltd.	1.00	-0.30	-23.08%
IL:MTLF	Matricelf Ltd.	256.70	-152.40	-37.25%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 27, 2026

Bioline Rx AI Stock Analysis